Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Arovella Confirms Nicole Van Der Weerden As CEO; Shareholders Reject Option Ratification

ALA: $0.050 +0.00% · MC: $60M

Arovella Therapeutics confirmed Nicole Van Der Weerden’s appointment as Chief Executive Officer, correcting an earlier announcement that described her role as acting CEO. Shareholders carried nine of ten AGM resolutions, rejecting ratification of a prior options issue; Arovella shares rose around 6% on the day, alongside the updates.

Source announcements: 2026-11-04 09:56 to 2026-11-04 14:36 Sydney time
Story updated 2026-11-04 14:40 Sydney time
SourcesArovella Appoints CEO2026 AGM PresentationCorrection to previous CEO appointment announcementResults of Meeting
Comments